

5/17/2016

## **Subcommittee on Antimicrobial Susceptibility Testing – Disclosure Summary**

### Personal, Professional, and Financial Interests

Relevant to the field(s) of work in which I would be involved with CLSI, I list below the organizations and activities with which I participate. For example, please list any controlling financial interest or benefit you may hold or have received including consulting fees or paid advisory boards, equity ownership/stock options or other information which your colleagues would need to know in order to fairly assess the basis of your position related to the CLSI activities (from past 3 years).

#### **Jean B. Patel, PhD, D(ABMM) – Chairholder Centers for Disease Control and Prevention**

Financial Interests or Benefits: None

#### **Melvin P. Weinstein, MD – Vice Chairholder Rutgers Robert Wood Johnson Medical School**

Financial Interests or Benefits: Research support in 2013-2015 from Beckman Coulter (Siemens), BD Diagnostics, and JMI Laboratories.

Research/speaker honorarium; T2 Biosystems

Consulted for Accelerate Diagnostics and Rempex Pharmaceuticals.

#### **Richard B. Thomson, Jr., PhD- Chairholder, Microbiology Expert Panel Evanston Hospital, NorthShore University HealthSystem**

Financial Interests or Benefits: Received honoraria, consulting fees or research funding in the past three years from International Health Management Associates, BD Kiestra, Nanosphere, and 5 not-for-profit universities and microbiology societies.

#### **Mary Jane Ferraro, PhD, MPH, Vice Chairholder, Microbiology Expert Panel Massachusetts General Hospital**

Financial Interests or Benefits: Research grants to institution from bioMerieux and BD.

#### **Members:**

#### **George M. Eliopoulos, MD Beth Israel Deaconess Medical Center**

Financial Interests or Benefits:

Advisory Boards – Bayer, Durata, Nabriva, Paratek, Rempex, and Theravance

Consultation - Shionogi

#### **Stephen G. Jenkins, PhD, D(ABMM),F(AAM) New York Presbyterian Hospital**

Financial Interests or Benefits:

Advisory boards for Bayer, Cempra, Cormedix, Insmmed, and Merck.

#### **James S. Lewis, II, PharmD, FIDSA Oregon Health & Science University**

Financial Interests or Benefits:

Consultant for – Accelerate Diagnostics, Achaogen, Allergan, Astellas, Merck, Medicines Company, Paratek, and Theravance

Speakers Bureau – Astellas, Forest, Merck

5/17/2016

**Brandi Limbago, PhD**  
**Centers for Disease Control and Prevention**

Financial Interests or Benefits: None

**Amy Mathers, MD**  
**University of Virginia Medical Center**

Financial Interests or Benefits:  
Research: Rempex Pharmaceuticals  
Consultant for Rempex Pharmaceuticals, Accelerate Diagnostics

**Tony Mazzulli, MD, FRCP(C), FACP**  
**Mount Sinai Hospital**

Financial Interests or Benefits:  
President: Canadian Association of HIV Clinical Laboratory Specialists  
Speaker Honorarium: Abbott, Merck, Roche  
Advisory Board: bioMerieux, Qvella Corporation, Pfizer, Roche  
Member, Executive Committee, CANCAST

**Robin M. Patel, MD**  
**Mayo Clinic**

Financial Interests or Benefits: Employee of Mayo Clinic  
Research funding: BioFire, Check-Points, Curetis, 3M, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, The Medicines Company, NIH  
Consultant: Curetis, Roche, Diaxonhit, Qvella  
Stipends: Journal of Clinical Microbiology, Clinical Infectious Diseases, Manual of Clinical Microbiology  
Co-Chair, ASM Microbe Program Planning Committee  
Patents: *B. pertussis* and *parapertussis* PCR, anti-biofilm substance, device/method for sonication  
Honoraria: USMLE, Up-to-Date, Infectious Diseases Board Review Course, NIH

**Sandra S. Richter, MD, D(ABMM)**  
**Cleveland Clinic**

Financial Interests or Benefits:  
Research grants – BD Diagnostics, OpGen, bioMerieux, Nanosphere, Cerexa, Pocared, Biofire Diagnostics, Achaogen Pharmaceuticals, Roche  
Speaker honorarium – bioMerieux  
Editor stipen – Journal of Clinical Microbiology, Manual of Clinical Microbiology

**Michael J. Satlin, MD, MS**  
**Weill Cornell Medical College/ NewYork-Presbyterian Hospital**

Financial Interests or Benefits: none  
Research grants/contract: Achaogen, Allergan

**John D. Turnidge, MD**  
**Australian Commission for Safety and Quality in Health Care**

Financial Interests or Benefits:  
Advisory boards for Novartis Australia, Pfizer Australia and AstraZeneca Australia  
Visiting speaker for bioMerieux

5/17/2016

**Barbara L. Zimmer, PhD**  
**Beckman Coulter, Inc.**

Financial Interests or Benefits: Employee of Beckman Coulter, Inc. which purchased the Microbiology Business Unit (MicroScan) from Siemens Healthcare Diagnostics 2/1/15

**Advisors:**

**Jeff Alder, PhD**  
**Bayer HealthCare Pharmaceuticals**

Financial Interests or Benefits: Employee and stockholder for Bayer HealthCare Pharmaceuticals

Other: NIH/NIAID grant and contract reviewer.

**Patricia A. Bradford, PhD**  
**AstraZeneca**

Financial Interests or Benefits: Employee of AstraZeneca Pharmaceuticals

**William B. Brasso, BS**  
**BD Diagnostic Systems**

Financial Interests or Benefits: Employee of BD Diagnostic Systems

**Dr. Rafael Canton**  
**ESCMID and EUCAST**

Financial Interests or Benefits: Ad-hoc member of the ESCMID (the European Society of Clinical Microbiology and Infectious Diseases) Executive Committee. Chairman of EUCAST (European Committee of Antimicrobial Susceptibility Testing).

**Graeme Forrest, MBBS**  
**Portland VA Healthcare System**

Financial Interests or Benefits: None

**Marcelo Galas**  
**National Institute of Infections Diseases, Ministry of Health**

Financial Interests or Benefits: None

**Howard Gold, MD**  
**Beth Israel Deaconess Medical Center**

Financial Interests or Benefits: None

**Janet A. Hindler, MCLS, MT(ASCP)**  
**UCLA Health System**  
**APHL**

Financial Interests or Benefits:

Speaker's Honoraria: bioMerieux, Inc.; Association of Public Health Labs  
Consultant: Accelerate Diagnostics, Inc.

5/17/2016

**Romney M Humphries, PhD D(ABMM)**  
**UCLA David Geffen School of Medicine**

Financial Interests or Benefits:

Research grants to institution- bioMerieux, Beckman Coulter, GenMark, Curetis, BD, Accelerate Diagnostics, Qiagen,  
Speaker Honorarium – Merck, Allergan  
Advisory Board – Nanosphere, Roche, Cepheid

**Thomas J. Kirn, Jr., MD, PhD**  
**Rutgers Robert Wood Johnson Medical School**

Financial Interests or Benefits:

Honorarium – Accelerate Diagnostics, Roche, BD

**Linda A. Miller, PhD**  
**GlaxoSmithKline**

Financial Interests or Benefits: Employee of GlaxoSmithKline Pharmaceuticals

**Melissa B. Miller, PhD, D(ABMM)**  
**University of North Carolina School of Medicine**

Financial Interests or Benefits: None

**Greg Moeck, PhD**  
**The Medicines Company**

Financial Interests or Benefits: Employee of The Medicines Company

**Sumati Nambiar, MD, MPH**  
**FDA Center for Drug Evaluation and Research**

Financial Interests or Benefits: None

**David P. Nicolau PharmD, FCCP, FIDSA**  
**Hartford Hospital**

Financial Interests or Benefits:

Consultant, grant recipient and/or on the speaker's bureau for the following entities: Achaogen, Actavis, Bayer, Cepheid, Merck, Pfizer, Macrolide Pharmaceuticals, Melinta, Tetrphase, The Medicines Company, Shionogi.

**Helio S. Sader, MD, PhD**  
**JMI Laboratories**

Financial Interests or Benefits: JMI Laboratories, Inc. has also received research and educational grants in 2012-2014 from Achaogen, Actelion, Affinium, American Proficiency Institute (API), AmpliPhi Bio, Anacor, Astellas, AstraZeneca, Basilea, BioVersys, Cardeas, Cempra, Cerexa, Cubist, Daiichi, Dipexium, Durata, Fedora, Forest, Furiex, Genentech, GlaxoSmithKline, Janssen, Johnson & Johnson, Medpace, Meiji Seika Pharma, Melinta, Merck, Methylgene, Nabriva, Nanosphere, Novartis, Pfizer, Polyphor, Rempex, Roche, Seachaid, Shionogi, Synthes, The Medicines Co., Theravance, ThermoFisher, Venatorx, Vertex and Waterloo. Some JMI employees are advisors/consultants for Astellas, Cubist, Pfizer, Cempra, Cerexa-Forest, and Theravance. In regards to speakers bureaus and stock options-none to declare.

5/17/2016

**Paul C. Schreckenberger, PhD, D(ABMM), F(AAM)**  
**Loyola University Medical Center**

Financial Interests or Benefits:

**Speaker Bureau:** Merck & Company,

**Research Grants:** Accelerate Diagnostics, Becton Dickinson, Beckman Coulter, BioFire, bioMerieux, Bruker, Center for Anti-Infective Research and Development (CAIRD), Cepheid, International Health Management Associates (IHMA), JMI Laboratories, Kimberly-Clark, Honorarium: Accelerate Diagnostics, Beckman-Coulter, BioFire, Cepheid, Hardy Diagnostics, ThermoFisher

Advisory Boards: BioFire, Cembra Inc., Cepheid, GenMark, Quidel, ThermoFisher, Merck

**Audrey N. Schuetz, MD, MPH, D(ABMM)**  
**Mayo Clinic**

Financial Interests or Benefits: None

**Susan E. Sharp, Ph.D., DABMM, FAAM**  
**ASM**

Financial Interests or Benefits: None

**Ribhi M. Shavar, Ph.D, D(ABMM)**  
**FDA Ctr. For Devices/Rad. Health**

Financial Interests or Benefits: None

**Pranita Tamma, MD, MHS**  
**John Hopkins University School of Medicine**

Financial Interests or Benefits:

Research grant funded jointly by Pfizer and The Joint Commission entitled “What is the Optimal Antimicrobial Stewardship Strategy: Pre-Prescription Authorization or Post-Prescription Review and Feedback?”

Investigator-initiated grant funded by Merck entitled “The effectiveness of piperacillin-tazobactam versus ertapenem for the treatment of intra-abdominal infections involving Enterococcus faecalis.”

**Kazuhiro Tateda, MD, PhD**  
**Toho University School of Medicine**

Financial Interests or Benefits: None

**Maria M. Traczewski, BS, MT(ASCP)**  
**The Clinical Microbiology Institute**

Financial Interests or Benefits:

CMI has received research grants/contracts past and present from the following companies: AstraZeneca, Cubist, ContraFect, GlaxoSmithKline, Pfizer, Pfizer Animal Health, Merck, Astellas, Theravance, Novartis, Paratek, Merck Animal Health, Elanco, Cardeas, BioMerieux, Gilead, Intervet, Vertex, Cornerstone Therapeutics, Cerexa, Shering-Plough Vet. Division, MAP Pharmaceuticals, APP Pharmaceuticals, Novoxel, Protez, Leo, Oscient, Achaogen, Trius, Replidyne, Bausch and Lomb, Blanca, Johnson & Johnson, Wyeth, Sanofi-Aventis, Dechra Pharmaceuticals, APP Pharmaceuticals, Symbiomix Therapeutics, Cepheid Inc., Beckman-Seimans, Advanced Food Technologies, Becton-Dickinson, Stanford University, Dermira Inc. and Basilea Pharmaceutica.